Kraig Biocraft Laboratories Ends Quiet Period
July 01 2013 - 6:05AM
Kraig Biocraft Laboratories, Inc. (OTCQB:KBLB) (the "Company"), the
leading developer of advanced spider silk based fibers, today
announced the end of the quiet period phase related to its recently
filed S1 financing registration and a second potential financing
that the Company has now terminated.
"We are very happy to be able to announce the end of this quiet
period, and we want to thank our shareholders for their patience,"
said Company CEO and founder, Kim K Thompson. "Quiet periods during
times when certain financings are being prepared are a normal part
of the Company's regulatory compliance obligations. While it
is wonderful to receive the underlying finance, the quiet periods
themselves are an unwelcome, but necessary burden. Having
successfully carried that burden, we are now very happy to set it
down."
During the quiet period, the Company was unable, from its
perspective, to effectively disseminate corporate information
announcements and public relations announcements. The Company
had come to terms with a New York based investment banking firm for
a potential financing (in addition to the financing described in
the recently filed S1) that would have necessitated a second S1
registration. The Company has determined however that the
burden of an additional quiet period, or any further open ended
extension of the quiet period, would be too
counterproductive. The Company is looking forward to resuming
more open communications with the financial markets and
shareholders.
About Kraig Biocraft Laboratories, Inc.
Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully
reporting biotechnology company is the leading developer of
genetically engineered spider silk based fiber technologies. The
Company has achieved a series of scientific breakthroughs in the
area of spider silk technology with implications for the global
textile industry.
Cautionary Statement Regarding Forward Looking Information
Statements in this press release about the Company's future and
expectations other than historical facts are "forward-looking
statements." These statements are made on the basis of management's
current views and assumptions. As a result, there can be no
assurance that management's expectations will necessarily come to
pass. These forward-looking statements generally can be identified
by phrases such as "believes," "plans," "expects," "anticipates,"
"foresees," "estimated," "hopes," "if," "develops," "researching,"
"research," "pilot," "potential," "could" or other words or phrases
of similar import. Forward looking statements include descriptions
of the Company's business strategy, outlook, objectives, plans,
intentions and goals. All such forward-looking statements are
subject to certain risks and uncertainties that could cause actual
results to differ materially from those in forward-looking
statements.
This press release does not constitute an offer to sell or the
solicitation of an offer to buy any security.
CONTACT: Ben Hansel, Hansel Capital, LLC.
(720) 288-8495
ir@KraigLabs.com
Kraig Biocraft Laborator... (QB) (USOTC:KBLB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Kraig Biocraft Laborator... (QB) (USOTC:KBLB)
Historical Stock Chart
From Apr 2023 to Apr 2024